Last reviewed · How we verify
NCT03546933: MAGNET ACS
VitalScan MCG Rule-out Multi-centre Pivotal Study - US
trial testing VitalScan Magnetocardiograph in Acute Coronary Syndrome in 651 participants. Terminated before completion.
6 August 2019
Quick facts
| Lead sponsor | Creavo Medical Technologies Ltd |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 651 |
| Start date | 17 July 2018 |
| Primary completion | 6 August 2019 |
| Estimated completion | 6 August 2019 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- VitalScan Magnetocardiograph
Conditions studied
- Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →
Sponsor
Creavo Medical Technologies Ltd
Who can join
18 and older, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective multi-centre observational study to validate the diagnostic accuracy of a transportable magnetocardiograph device for acute coronary syndrome (ACS), focusing on rule-out capability, in patients who present to the emergency department with chest pain symptoms consistent with ACS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03546933
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VitalScan Magnetocardiograph
Trials testing the same drug.
- NCT02921438 — VitalScan MCG Rule-out Multi-centre Pivotal Study - UK · completed
Other recruiting trials for Acute Coronary Syndrome
Currently open trials in the same condition.
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
- NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
- NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting
Other Creavo Medical Technologies Ltd trials
Trials by the same sponsor.
- NCT03358368 — MCG Post Myocardial Infarction Study · completed
- NCT02921438 — VitalScan MCG Rule-out Multi-centre Pivotal Study - UK · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03546933 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Creavo Medical Technologies Ltd
- Last refreshed: 18 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03546933.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing